Search clinical trials for: Dapagliflozin

Total 566 results

Osaka University

Unknown

Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) (DAPHNIS)

Diabetes Mellitus, Type 2

Japan
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
University of Dundee
European Foundation for the Study of Diabetes

Completed

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes (REFORM)

Heart Failure | Diabetes

United Kingdom
Chiang Mai University

Completed

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Diabetes Mellitus, Type 2 | Ischemic Heart Disease

Thailand
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
Prof. Dr. Thomas Forst

Completed

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Type2 Diabetes Mellitus

Germany
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Slotervaart Hospital
AstraZeneca; Spaarne Gasthuis; Isala

Completed

Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (GluCon-COPD)

Hyperglycemia Steroid-induced

Netherlands
University of Erlangen-Nürnberg Medical School

Completed

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content (Dapa)

Diabetes Mellitus Type 2

Germany
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Hypertension | Obesity | Diabetes Mellitus, Type 2 | Blood Pressure | Vascular Stiffness | Cardiac Hypertrophy | Microalbuminuria

Brazil
AstraZeneca
Optum, Inc.

Completed

Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

Diabetes Mellitus Type 2

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
AstraZeneca Turkey
Optimum Contract Research Organization, Turkey

Completed

Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey (DAPA-TURK)

Type 2 Diabetes Mellitus

Turkey
Kinderkrankenhaus auf der Bult
AstraZeneca; Alcedis GmbH

Completed

Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes (DapaDream)

Type1diabetes

Germany
University of Palermo
AstraZeneca; University of Catania

Unknown

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Type 2 Diabetes Mellitus

Italy
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
AstraZeneca
Antaros Medical; Bioventure Hub; 43183 Mölndal; Sweden

Completed

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus (DERISC)

Type 2 Diabetes Mellitus

Finland
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
University Health Network, Toronto
AstraZeneca; University of Toronto; Toronto General Hospital

Completed

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (TRANSLATE)

Focal Segmental Glomerulosclerosis

Canada
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Janssen Research & Development, LLC

Completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Sheba Medical Center
European Union

Unknown

Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy (SMC 0712-13)

Brain Neoplasms

Israel
AstraZeneca
AstraZeneca, Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

China, Korea, Republic of, India
Indonesia University

Completed

Effect of Neostigmine on the Recovery of Rocuronium: A Comparison Between Partial and TOF Ratio-Based Dose

General Anesthesia | Muscle Relaxant

Indonesia
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Phase III Insulin Add-On Asia Regional Program - ST

Diabetes

China, Korea, Republic of, Singapore
The Catholic University of Korea
AstraZeneca; Severance Hospital; Eulji General Hospital; Kyung Hee University Hospital...

Completed

Effect of Dapagliflozin on Glycemic Variability (DIVE)

Type 2 Diabetes Mellitus

Korea, Republic of
Seoul National University Hospital
Ipsen; Medical Research Collaborating Center, Seoul, Korea

Completed

A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia

Cervical Dystonia

Korea, Republic of
AstraZeneca

Completed

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Type II Diabetes

United States
AstraZeneca
Bristol-Myers Squibb

Completed

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Mexico
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
AstraZeneca
Bristol-Myers Squibb

Completed

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Canada, Mexico, India, Puerto Rico, Russian Federation, South Africa
IInstituto Gallego de Medicina Vascular

Unknown

Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

Diabetes Mellitus, Type 2

Spain
AstraZeneca
Uppsala Clinical Research, Uppsala, Sweden

Completed

A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients (EFFECTII)

T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Sweden
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Netherlands, Canada
Lawson Health Research Institute
AstraZeneca

Completed

Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin

Type 2 Diabetes Mellitus
Weill Medical College of Cornell University

Withdrawn

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (Dexlar)

Diabetes Mellitus, Type 2

United States
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Add-on to Thiazolidinedione (TZD) Failures

Type 2 Diabetes

Taiwan, United States, Argentina, Canada, Mexico, Puerto Rico, Philippines, India, Peru
Enrique Alday Muñoz

Completed

Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery

Major Abdominal Surgery

Spain
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Dyslipidemia
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Diabetes Mellitus, Type 2

Australia, United States, Italy, Argentina, Canada, Mexico, India, Peru, Spain, Denmark, France, Singapore, Puerto Rico
AstraZeneca
AstraZeneca, Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

China, Korea, Republic of, Taiwan, India
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Type 2 Diabetes

Mexico, Russian Federation, Spain, United States, Canada, Puerto Rico, Hungary, Peru, Romania, Poland, Germany, Czech Republic, India, Colombia, Denmark, Finland
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Type 2 Diabetes

Australia, United States, Canada, Mexico, Puerto Rico, Germany, Hungary, Ireland, Poland, Romania, Denmark, Czech Republic, India, Colombia, Finland, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Drug Interaction With Metformin

Healthy Male and Female Subjects

United States
Uppsala University
AstraZeneca

Completed

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Sweden

3

Subscribe